LNK mutation analysis was performed in 61 patients with blast-phase myeloproliferative neoplasms (MPN); post-primary myelofibrosis (PMF) in 41, post-polycythemia vera in 11 and post-essential thrombocythemia in 9 patients. Paired chronicblast phase sample analysis was possible in 26 cases. Nine novel heterozygous LNK mutations were identified in eight (13%) patients: six exon 2 missense mutations involving codons 215, 220, 223, 229 and 234, a synonymous mutation involving codon 208, and two deletion mutations involving exon 2 (685-691_delGGCCCCG) or exon 5 (955_delA); eight affected the pleckstrin homology (PH) domain. Mutations were detected in six (9.8%) blast-phase samples; chronic-phase sample analysis in four of these revealed the same mutation in one. Mutant LNK was detected in chronic-phase only in two patients and in both chronic-blast phases in one. JAK2V617F was documented in three and IDH2R140Q in one LNK-mutated patients. LNK mutations were not detected in 78 additional patients with chronic-phase MPN enriched for TET2, IDH, JAK2V617F, or MPL-mutated cases. We conclude that LNK mutations (i) target an exon 2 'hot spot' in the PH domain spanning residues E208-D234, (ii) might be more prevalent in blast-phase PMF and (iii) are not mutually exclusive of other MPN-associated mutations but rarely occur in their presence in chronic-phase disease.
Introduction
Constitutively activated JAK2 has an essential role in the pathogenesis of BCR-ABL1-negative chronic myeloproliferative neoplasms (MPN), namely, polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). 1 Aberrant JAK-STAT signaling in MPN has been attributed to acquisition of JAK2V617F mutation (PV 96%, PMF 65%, ET 55%), 2 JAK2 exon 12 mutations (PV 3%) 3 or MPL exon 10 mutations (PMF 10%, ET 3%), 4 however MPN cases without identifiable mutations in the aforementioned genes also exhibit aberrant JAK-STAT activation.
Recent studies have focused on the role of LNK (SH2B3), which is an adaptor protein with several domains (a proline-rich dimerization domain (Phe_Zip), a pleckstrin homology (PH) domain for localization to cell membrane, and a SH2 domain that binds to MPL and JAK2) in the pathogenesis of MPN. LNK is a negative regulator of thrombopoietinFthrombopoietin receptor (MPL)-mediated JAK2 activation; LNK-deficient mice exhibit increased number of megakaryocytes with increased ploidy, 5 increased number of erythrocyte progenitors, 6 as well as an expanded hematopoietic stem cell pool with enhanced self renewal. 7 LNK has been shown to down regulate signaling downstream of MPLW515L and JAK2V617F in vitro. 8, 9 Indeed, in a transduction-transplant murine model, LNK deficiency accelerates and exacerbates MPN development induced by TEL-JAK2 and JAK2V617F. 10 In this model, physical interaction between JAK2V617F and LNK was required for the latter's ability to restrain PV/MF expression; similarly LNK's SH2 domain was required for its ability to restrain TEL-JAK2 induced myeloid expansion in this model.
Recently, 33 patients with JAK2V617F-negative MPN were screened for mutations in LNK; of these, two cases (prevalence 6%; one each with PMF and ET) harbored mutations leading to disruption of the LNK protein. 11 Both mutations were somatic, and disrupted either PH and SH2 domains concurrently, or PH domain alone. Similar to JAK2V617F and MPLW515L, LNK mutations were associated with expansion of a myeloid progenitor population characterized by cytokine-responsive p-STAT3 þ /5 þ expression. These data provided direct evidence that disruption of an inhibitor of JAK-STAT signaling phenocopies disease related to activating mutation in tyrosine kinases/cytokine receptors.
In this study, we report on LNK mutation analysis in a relatively large cohort of blast-phase and chronic-phase MPN patients, including a subset for whom paired chronic-and blastphase samples were available, with the following goals: (i) to describe the prevalence of LNK mutations in blast-phase MPN, which has hitherto not been studied; (ii) to define the relationship of LNK mutation acquisition and leukemic transformation of MPN, through the study of paired sequential samples and (iii) to describe the prevalence of LNK mutations in chronicphase MPN patients known to harbor TET2, IDH, JAK2V617F or MPL mutations.
Materials and methods
This study was approved by the Mayo Clinic institutional review board. All patients provided authorization for use of their medical records for research purposes, and research was carried out according to the principles of the Declaration of Helsinki. We utilized the Mayo Clinic database of adult MPN and acute myeloid leukemia patients (age X18 years) to identify consecutive patients, in whom stored peripheral blood or bone marrow cells were available for DNA extraction. Clinical data and bone marrow histology were reviewed and the hematological diagnosis confirmed per the 2008 World Health Organization proposal. 12 DNA was extracted using Qiagen's DNA Mini extraction kit (Qiagen, Santa Clara, CA, USA). Screening for JAK2V617F, 13 MPL exon 10, 14 TET2 15 and IDH1/ IDH2
14 mutations was performed as previously described.
LNK mutation screening
In each 50 ml reaction, 200-500 ng of DNA template was added to 5 ml of 10 Â PCR Buffer (Roche Diagnostics, Indianapolis, IN, USA), 1.5 ml of deoxyribonucleotide triphosphate (10 mM of each), 0.5 ml of Taq Polymerase, and 2 ml each of a 10 mM stock of forward and reverse primers. Conditions for the PCR and primers are listed below for each domain tested (SH2 and PH domain primers were obtained from Oh et al.
11
) Cycling parameters for all amplifications used an initial denaturation step of 95 1C for 2 min, followed by 35 cycles of an initial melt at 95 1C for 30 s, annealing for 45 s (see below for annealing temperature for each PCR), extension at 72 1C for 40 s and a final extension step of 72 1C for 3 min. After amplification, the products were purified using QIAquick Spin Kit (Qiagen), and quality and size was assessed via 1.5% agarose gel. Sequencing was performed bi-directionally using two ABI PRISM 3730 Â l DNA Analyzers (96 capillary) (Applied Biosystems, Carlsbad, CA, USA). In the case of the PH domain, before sequencing, 1 ml of first round PCR product was further amplified by nested PCR (using nested primers) and all products were purified before sequencing.
PH exon 2 (first PCR annealing 53 1C, nested annealing 57 1C)
Subcloning of LNK mutations LNK deletion mutations were subcloned using TOPO TA Cloning Kit (Invitrogen, Carlsbad, CA, USA). After insertion of the PCR product into the TOPO vector, constructs were transformed into One Shot TOP10 Chemically Competent Cells (Invitrogen). Briefly, 2 ml of TOPO Cloning construct was added to one vial of TOP10 cells and incubated on ice for 30 min. Cells were heat shocked for 30 s at 42 1C and immediately placed on ice. After addition of 250 m SOC (super optimal broth with catabolite repression) medium, the cells were incubated at 37 1C for 1 h and gently shaken at 200 r.p.m. A portion of cells (25 ml) were inoculated onto a prewarmed LB agarose plate containing 100 mg/ml ampicillin and 40 mg/ml X-gal, and incubated inverted at 37 1C overnight. Resulting white colonies were individually selected and expanded in 3 ml of LB broth at 37 1C while being shaken at 150 r.p.m. After 24 h, the broth was centrifuged at 1800 r.p.m. for 5 min, supernatant was poured off, and resulting pellet containing cloned product was subjected to plasmid extraction using standard protocol from Invitrogen's PureLink Quick Plasmid Miniprep Kit. Purified products were sequenced by ABI PRISM 3730xl DNA Analyzers using plasmid specific sequencing primers provided with TOPO TA Cloning Kit.
Results
We studied a total of 139 patients for mutations in the Phe_Zip, PH and SH2 domains of the LNK gene (that is, exons 2 to 7). Our initial mutation screen was restricted to patients with post-MPN acute myeloid leukemia (that is, blast-phase MPN); of the 61 patients studied in this stage, 42 were males (median age ¼ 65 years; range ¼ 44 to 82 years). In terms of antecedent MPN, 41 patients had previous PMF, 11 PV and 9 ET. For 26 of 61 cases, we were able to analyze paired sequential samples from chronic-and blast-phases of disease for presence of LNK mutations. In this cohort, a total of eight patients (13%) were identified with one or more LNK mutations (Table 1) . Six patients (9.8%; cases no. 2-5, and 7-8) harbored LNK mutations in blast-phase. Of the four patients who were also evaluable for mutations in the antecedent chronic-phase (PMF), 1 one patient (case no.4) was found to harbor LNK mutations in both phases of the disease. Incidentally, we also identified two patients (cases no. 1 and 6) who harbored LNK mutations in chronic-phase (PMF), but not in blast-phase of the disease. Seven of eight (88%) LNK-mutated cases in this cohort had PMF during chronicphase; the remaining case had PV. None of the mutations identified in this study have been previously described. Nine independent mutations were identified in eight patients (Table 1 ) ( Figure 1 ); six were missense mutations, one a synonymous 624G4A; E208E mutation (patient no. 8), and two were deletion mutations present in the same case (patient no. 4). All of the missense mutations at codons 215, 220, 223, 229 and 234, as well as the synonymous mutation at codon 208 were located in exon 2 of LNK, which encodes for the PH domain. The larger (seven nucleotide; 'proximal') deletion mutation (685-691_delGG CCCCG; patient no. 4) was also located in exon 2 (PH domain), and overlapped with the 685G4A; G229S mutation (patient no. 7). The smaller (one nucleotide; 'distal') deletion mutation (955_delA; patient no. 4) was located in exon 5, just distal to the PH domain. The larger deletion mutation resulted in loss of two amino acid residues (G229 and P230) and a frame shift in the coding sequence with generation of a premature stop codon 47 codons downstream of the deletion. The smaller deletion mutation resulted in a frame shift and generation of a premature stop codon, five codons downstream of the deletion. Both deletion mutations were found in patient no. 4, and were present in both chronic-and blast-phases of the disease (Figure 2 ). In contrast, the two missense mutations (A223V and D234N) identified in case no. 5 were present only in blast-phase of the disease. In the cases with two LNK mutations, it remains unclear whether the mutations segregate to the same or different LNK alleles.
All nine mutations identified in this study were heterozygous; for patient no. 4, the PCR products of LNK exon 2 and four amplification were subcloned; resequencing of the cloned products confirmed presence of both deletion mutants.
Wherein possible, blast-phase MPN patients were screened for presence of other pathogenetically relevant mutations (Table 1) ; four patients (cases no. 1, 4, 7 and 8) concurrently carried the JAK2V617F mutation, and its presence was documented in both chronic-and blast-phase in the two patients (cases no. 1 and 4) where such analysis was possible. In contrast, none of the patients harbored a MPL exon 10 mutation. Only one patient (case no. 4) harbored a concurrent IDH mutation (IDH2R140Q), which was documented in both disease phases in this instance (Figure 2 ). Only two patients (cases no. 2 and 6) were screened for presence of TET2 mutations, and both cases were noted to have wild-type sequence in this regard.
In the second stage, we screened a total of 78 patients with chronic-phase MPN (PV ¼ 39; PMF ¼ 25 and ET ¼ 14) for Figure 1 DNA sequence traces showing the nine independent LNK mutations identified in the current cohort. Six are missense mutations, one a synonymous mutation (E208E) and two are deletion mutations (685-691_delGGCCCCG and 955_delA). The arrows indicate the nucleotide substitution for missense mutations, and start of deleted segment for the deletion mutations. Table 1 Clinical and molecular characteristics of LNK mutated patients with blast-phase myeloproliferative neoplasms, including those for whom sequential chronic-phase and blast-phase samples were available presence of LNK mutations in the PH domain only (Table 2) . For this analysis, we enriched for those cases known to harbor other mutations of pathogenetic relevance in this population, including JAK2V617F (n ¼ 66; 85%), TET2 (n ¼ 27; 35%), IDH (n ¼ 9; 12%) and MPL exon 10 (5; 7%). In this follow-up cohort, we failed to identify any cases with LNK mutations.
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Discussion
The recent identification of LNK mutations in a subset (6%) of cases with JAK2V617F-negative chronic-phase ET or PMF has further advanced our understanding of the molecular pathogenesis of MPN. 11 In the two LNK-mutated cases reported heretofore, the mutations were heterozygous in both instances, and disrupted the PH domain suggesting that LNK mislocalization is associated with a loss of its function. Functional studies revealed an exaggerated response of LNK-mutated primary cells to thrombopoietin or granulocyte colony-stimulating factor stimulation; loss of LNK function with the two mutations was not uniform however; the missense (E208Q) mutation resulted in a partial defect, with a more complete loss of function seen with the (603-607_delGCGCT; 613C4G) deletion mutation.
Given the implied low prevalence of LNK mutations in patients with chronic-phase MPN from the aforementioned study, we initially focused on patients with post-MPN acute myeloid leukemia (that is, blast-phase MPN) for LNK mutation screening. In this study, LNK mutation prevalence in blast-phase MPN patients was higher than previously reported for JAK2V617F-negative chronic-phase ET or PMF (9.8 versus 6%). Although all cases except one had antecedent PMF in this study, it is premature to infer any association of LNK mutations with this disease given that our cohort was enriched for PMF cases. In two cases, LNK mutations were demonstrable in chronic-phase but not blast-phase, and in one case the mutations were demonstrable in both disease phases. This observation suggests that LNK mutations may arise early in the disease course, and also that in some instances, LNK mutations present in chronic-phase may be 'lost' at the time of leukemic transformation, as has been described for JAK2V617F in this setting. 16 Consistent with a previous report, 11 nearly all the LNK mutations in this study localized to the PH domain, confirming the importance of this domain for LNK function. One mutation (955_delA; 'distal') however targeted LNK immediately downstream (that is, carboxy terminus) of the PH domain, with predicted protein truncation immediately distal to this site leading to loss of the SH2 domain. Inferring the pathogenetic impact of this particular mutation however is complicated by the observation that the same patient (case no. 4) harbored a concurrent deletion mutation (685_691_delGGCCCCG; 'proximal') within the PH domain. This study did not distinguish between whether the two mutations localize to the same LNK allele, or whether they represent a compound heterozygous state, which likely implies a more severe loss of LNK function. The same discussion regarding allelic segregation of two concurrent LNK mutations also applies to case no. 5. Surprisingly, none of the nine independent mutations in this study were identical to those identified in the study by Oh et al. 11 In this study, six missense mutations, the synonymous 624G4A; E208E mutation, and the 'proximal' deletion mutation (685_691_delGGCCCCG) appear to target a 'hot spot' in the PH domain spanning residues E208 to D234. The 'proximal' deletion mutation overlaps the 685G4A; G229S mutation, which supports the existence of a mutational 'hot spot'. Similarly, LNK G220 and E208 are also frequently mutated; in this study, two missense mutations (G220R and G220V) were found to target G220. With regards to E208, one mutation (E208Q) has been previously reported; 11 in this study, we also report the synonymous 624G4A; E208E mutation. In an independent study, we identified a 622G4T; E208X (glutamate to stop codon) mutation in a patient with JAK2 mutationnegative erythrocytosis (Lasho et al., in press). This observation of promiscuous mutations targeting (predominantly) a single exon (exon 2) of LNK is reminiscent of JAK2 exon 12 mutations observed in cases of JAK2V617F-negative PV.
3 JAK2 exon 12 mutations target a 'hot spot' spanning amino acid residues 536-547 (that is, 36 bases), and include point (K539L) or double (H538QK539L) mutations, a two-amino acid deletion (N542-E543del), a two-amino acid deletion followed by an insertion (F537-K539delinsL) and two relatively large duplications, namely V536-I546dup11 and F537-I546dup10 þ F547L.
To clarify genotype-phenotype association(s), we screened blast-phase MPN patients for presence of additional MPN relevant mutations. Approximately half of the LNK-mutated cases concurrently harbored JAK2V617F. In most of the instances, the JAK2V617F mutant allele burden was o50% indicating the JAK2V617F was present in the heterozygous state. Similarly, LNK mutations were also uniformly heterozygous in these cases. This study did not distinguish whether JAK2V617F and LNK mutations coexisted in the same clone or whether they represented two independent clones. For blast-phase MPN, we failed to identify a clearly discernible genotype-phenotype correlation whether for any single mutation or a particular combination of mutations; these data are similar to other studies of blast-phase MPN that have revealed multiple mutation combinations, as well as sequencing events for mutation acquisition, during the course of disease evolution.
14,17 Analysis of chronic-phase MPN samples suggested that LNK mutations segregate at low frequency with TET2, IDH and MPL mutations. This conclusion remains tentative pending confirmation in a larger cohort of MPN patients.
One particularly interesting case is patient no. 4 who exhibited four separate mutations (that is, JAK2V617F, IDH2R140Q, LNK 685_691_delGGCCCCG and LNK 955_delA); all four mutations were present in both chronicand blast-phase of the disease (Figure 2 ). This case illustrates the incredibly complex clonal hierarchy of MPN, which has implications for molecularly targeted therapies for MPN such as the orally bioavailable JAK-1/2 inhibitors that are currently being evaluated in clinical trials.
There are several inferences that can be drawn from the aforementioned observations. First, LNK mutations are relatively infrequent in chronic-phase MPN, at least in those cases enriched for JAK2V617F, TET2, IDH and/or MPL mutations. In contrast, LNK mutation frequency may be higher in blast-phase MPN, suggesting that LNK mutations may be associated with leukemic transformation. However, the presence of the mutation in paired chronic-and blast-phase samples suggests that, at least in some cases, LNK mutations arise early in the disease course. Second, the identification of multiple mutations concentrated largely in a single exon of LNK is reminiscent of the mutational 'hot spot' observed in JAK2 exon 12-mutated PV cases. Third, although LNK mutations may occur concurrently with JAK2V617F or IDH mutations in blast-phase MPN, there is no clearly discernible genotype-phenotype correlation to date. Fourth, two LNK mutations may coexist in a given individual; additional studies are indicated to discern whether this reflects a compound heterozygous state. Lastly, analysis of LNK mutations, within the context of other MPN-relevant mutations, reinforces the clonal complexity of MPN.
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